tetano
Editor, Senior Moderator
Diseases
. 2020 Sep 23;8(4):E36.
doi: 10.3390/diseases8040036.
Serological Tests for SARS-CoV-2 Coronavirus by Commercially Available Point-of-Care and Laboratory Diagnostics in Pre-COVID-19 Samples in Japan
Zhaoqing Lyu[SUP] 1 [/SUP], Mariko Harada Sassa[SUP] 1 [/SUP], Tomoko Fujitani[SUP] 1 [/SUP], Kouji H Harada[SUP] 1 [/SUP]
Affiliations
Abstract
The number of COVID-19 patients in Japan is considered low, compared with U.S. and European countries. However, recent serological survey reported that several percent of population showed IgG positive to SARS-CoV-2. Specificity in the assays might influence the estimate, and possibility of overdiagnosis should be investigated. Serological tests for SARS-CoV-2 coronavirus were performed in pre-COVID-19 sera in Japan (400 healthy subjects in 2012-2015). Lateral flow assay (LFA) and enzyme-linked immunosorbent assay (ELISA) showed 1.5% (6/400) and 1.75% (7/400) IgG positives, respectively. Among those false positive samples, only one sample was positive in both LFA and ELISA (0.25%; 95% CI: 0.006-1.39%). Possible bias from pooling method was examined by Monte Carlo method and the possibility was unlikely at low false positive rate. Previous surveys might overestimate COVID-19 seroprevalence in several populations of Japan. These false positives could be excluded by combination of different diagnostics. Nonetheless, the result of seroprevalence should be carefully interpreted in less prevalent areas.
Keywords: ELISA; Japan; LFA; SARS-CoV-2; false positive rate; serological test; specificity.
. 2020 Sep 23;8(4):E36.
doi: 10.3390/diseases8040036.
Serological Tests for SARS-CoV-2 Coronavirus by Commercially Available Point-of-Care and Laboratory Diagnostics in Pre-COVID-19 Samples in Japan
Zhaoqing Lyu[SUP] 1 [/SUP], Mariko Harada Sassa[SUP] 1 [/SUP], Tomoko Fujitani[SUP] 1 [/SUP], Kouji H Harada[SUP] 1 [/SUP]
Affiliations
- PMID: 32977485
- DOI: 10.3390/diseases8040036
Abstract
The number of COVID-19 patients in Japan is considered low, compared with U.S. and European countries. However, recent serological survey reported that several percent of population showed IgG positive to SARS-CoV-2. Specificity in the assays might influence the estimate, and possibility of overdiagnosis should be investigated. Serological tests for SARS-CoV-2 coronavirus were performed in pre-COVID-19 sera in Japan (400 healthy subjects in 2012-2015). Lateral flow assay (LFA) and enzyme-linked immunosorbent assay (ELISA) showed 1.5% (6/400) and 1.75% (7/400) IgG positives, respectively. Among those false positive samples, only one sample was positive in both LFA and ELISA (0.25%; 95% CI: 0.006-1.39%). Possible bias from pooling method was examined by Monte Carlo method and the possibility was unlikely at low false positive rate. Previous surveys might overestimate COVID-19 seroprevalence in several populations of Japan. These false positives could be excluded by combination of different diagnostics. Nonetheless, the result of seroprevalence should be carefully interpreted in less prevalent areas.
Keywords: ELISA; Japan; LFA; SARS-CoV-2; false positive rate; serological test; specificity.